Yasir Al-Wakeel
Director/Board Member en MAXCYTE, INC. .
Fortuna: 449 933 $ al 31/03/2024
Perfil
Yasir Baha Al-Wakeel is an Independent Non-Executive Director at MaxCyte, Inc. He previously worked as Treasurer, Chief Financial & Accounting Officer at Merrimack Pharmaceuticals, Inc. and as a Research Analyst at Credit Suisse Securities (Europe) Ltd.
He also served as the Chief Financial Officer at BioNTech US, Inc. and currently holds the position of CFO, CAO & Head-Corporate Development at Kronos Bio, Inc. Dr. Al-Wakeel holds a doctorate degree from the University of Oxford and a graduate degree from the University of Cambridge.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
KRONOS BIO INC
0.58% | 06/07/2023 | 346 102 ( 0.58% ) | 449 933 $ | 31/03/2024 |
MAXCYTE, INC.
-.--% | 22/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Yasir Al-Wakeel
| Empresas | Cargo | Inicio |
|---|---|---|
| MAXCYTE, INC. | Director/Board Member | 15/06/2021 |
Antiguos cargos conocidos de Yasir Al-Wakeel.
| Empresas | Cargo | Fin |
|---|---|---|
| KRONOS BIO, INC. | Director of Finance/CFO | 15/09/2023 |
| NEON THERAPEUTICS, INC. | Director of Finance/CFO | 01/05/2020 |
| MERRIMACK PHARMACEUTICALS, INC. | Director of Finance/CFO | 01/07/2017 |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Analyst-Equity | 01/06/2015 |
Formación de Yasir Al-Wakeel.
| University of Oxford | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| KRONOS BIO, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Credit Suisse Securities (Europe) Ltd.
Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Finance |
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Yasir Al-Wakeel
